Oxford Biomedica

Oxford Biomedica, a Biological Product (except Diagnostic) Manufacturing company based in GB, reported total carbon emissions of approximately 66,272 tonnes CO2e in 2025. This includes about 2,425 tonnes CO2e from Scope 1 emissions, 1,337 tonnes CO2e from Scope 2 (market-based), and 62,510 tonnes CO2e from Scope 3 emissions.

In 2024, the company's total emissions were approximately 83,941 tonnes CO2e, comprising around 2,415 tonnes CO2e from Scope 1, 1,747 tonnes CO2e from Scope 2 (market-based), and 79,779 tonnes CO2e from Scope 3. This represents a decrease in total emissions of approximately 21% between 2024 and 2025.

Oxford Biomedica has set ambitious climate commitments. The company aims to achieve a 42% absolute reduction in Scope 1 and Scope 2 GHG emissions by 2030 from a 2021 base year. They also plan to increase active annual sourcing of renewable electricity from 29.1% in 2021 to 100% by 2030. Furthermore, Oxford Biomedica is committed to ensuring that 90% of its suppliers, by emissions covering purchased goods and services, will have science-based targets by 2029. These near-term targets are classified as consistent with reductions required to keep warming to 1.5°C by the Science Based Targets initiative (SBTi). The company is on track to meet its two-year targets for Scope 1 emissions. Oxford Biomedica has also made a commitment to net-zero, though this commitment has since been removed.